Mizon Charlotte, Piva Frank, Queyrel Viviane, Balduyck Malika, Hachulla Eric, Mizon Jacques
Laboratoire de Biochimie, Faculté de Pharmacie, UPRES E.A. 2681, Lille, France.
Clin Chem Lab Med. 2002 Jun;40(6):579-86. doi: 10.1515/CCLM.2002.100.
Bikunin (BK) is a Kunitz-type proteinase inhibitor responsible for most of the antitryptic activity of urine and so is known as the urinary trypsin inhibitor. As its excretion increases in inflammatory conditions, it is often considered to be a positive acute phase protein (APP). However, the gene for BK is downregulated in inflammation. In human plasma the major part of BK is covalently linked through a glycosaminoglycan chain to one or two homologous peptide heavy chains, thus forming high molecular weight proteinase inhibitors called pre-alpha-inhibitor (PalphaI) and inter-alpha-inhibitor (IalphaI), respectively. The C-terminal parts of these heavy chains are very sensitive to proteolysis. Neutrophil proteinases in particular are able to release from IalphaI and PalphaI BK (M, about 25,000) which retains its antitryptic activity and is quickly excreted in urine. It was therefore an early supposition that the higher urinary excretion of BK occurring during inflammatory diseases should be, at least in some respect, related to a partial proteolysis of IalphaI and PalphaI. In this study we observed that BK, determined as antitryptic activity, was clearly increased in urine from 35 patients with inflammatory diseases varying in origin and severity (76.5 +/- 75.5 IU/g vs. reference value <10 IU/g creatinine). This increase seems mainly to be associated with polymorphonuclear leukocyte activation, monitored by human leukocyte elastase (HLE) determination rather than with the acute phase response assessed by C-reactive protein (CRP) measurement. For all the patients we found that the urinary levels of BK and serum concentration of intact IalphaI correlated inversely (r=-0.36; p=0.03), in agreement with the presumed precursor-product relationship linking IalphaI and BK. We also proved that urinary BK was significantly higher, and serum IalphaI was significantly lower, in samples with plasma HLE values above the reference: 90 microg/l. Taken together, our results demonstrate that BK, the urinary excretion of which is increased in inflammatory conditions, originates, at least partly, from IalphaI and PalphaI by proteolytic cleavage. Consequently, urinary BK determination provides information on the severity of systemic proteolysis occurring in inflammation. We also demonstrated that during inflammatory diseases IalphaI and PalphaI concentrations in serum are dependent on their increased utilization as well as on the regulation of their biosynthesis.
bikunin(BK)是一种Kunitz型蛋白酶抑制剂,它负责尿液中大部分的抗胰蛋白酶活性,因此被称为尿胰蛋白酶抑制剂。由于其在炎症条件下排泄增加,它常被认为是一种阳性急性期蛋白(APP)。然而,BK基因在炎症中表达下调。在人血浆中,BK的主要部分通过糖胺聚糖链与一或两条同源肽重链共价连接,从而分别形成称为前α抑制剂(PalphaI)和α间抑制剂(IalphaI)的高分子量蛋白酶抑制剂。这些重链的C末端部分对蛋白水解非常敏感。特别是中性粒细胞蛋白酶能够从IalphaI和PalphaI中释放出BK(分子量约25,000),其保留抗胰蛋白酶活性并迅速经尿液排泄。因此,早期推测炎症性疾病期间尿液中BK排泄增加至少在某些方面应与IalphaI和PalphaI的部分蛋白水解有关。在本研究中,我们观察到以抗胰蛋白酶活性测定的BK在35例起源和严重程度各异的炎症性疾病患者的尿液中明显增加(76.5±75.5 IU/g,而参考值<10 IU/g肌酐)。这种增加似乎主要与通过人白细胞弹性蛋白酶(HLE)测定监测的多形核白细胞活化有关,而非与通过C反应蛋白(CRP)测量评估的急性期反应有关。对于所有患者,我们发现尿液中BK水平与完整IalphaI的血清浓度呈负相关(r = -0.36;p = 0.03),这与连接IalphaI和BK的假定前体-产物关系一致。我们还证明,在血浆HLE值高于参考值90μg/l的样本中,尿液BK显著更高,血清IalphaI显著更低。综上所述,我们的结果表明,BK在炎症条件下尿液排泄增加,至少部分源于IalphaI和PalphaI的蛋白水解裂解。因此,尿液BK测定提供了炎症中发生的全身蛋白水解严重程度的信息。我们还证明,在炎症性疾病期间,血清中IalphaI和PalphaI的浓度取决于它们增加的利用率以及它们生物合成的调节。